Difference between revisions of "HAEM4:Monoclonal Immunoglobulin Deposition Diseases"
Jump to navigation
Jump to search
Bailey.Glen (talk | contribs) (Created page with "==Primary Author(s)*== Chen Yang, MD, PhD __TOC__ ==Graphical Data Links== None ==General Disease Overview / Description of Cancer Category== *The major classification g...") |
Bailey.Glen (talk | contribs) |
||
| Line 11: | Line 11: | ||
==General Disease Overview / Description of Cancer Category== | ==General Disease Overview / Description of Cancer Category== | ||
| − | *The major classification group of Monoclonal Immunoglobulin Deposition Diseases, as described in the revised 4th edition of the WHO, includes the categories: [[ | + | *The major classification group of Monoclonal Immunoglobulin Deposition Diseases, as described in the revised 4th edition of the WHO, includes the categories: [[HAEM5:Immunoglobulin-related (AL) amyloidosis]] and [[HAEM5:Monoclonal immunoglobulin deposition disease]] |
*The monoclonal immunoglobulin (Ig) deposition diseases are closely related disorders characterized by deposition of aberrant Ig (mostly light chain and rarely heavy chain) in various tissues, leading to organ dysfunction<ref>McKenna RW, et al., (2017). Plasma cell neoplasms: Monoclonal immunoglobulin deposition diseases, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p254-256.</ref> | *The monoclonal immunoglobulin (Ig) deposition diseases are closely related disorders characterized by deposition of aberrant Ig (mostly light chain and rarely heavy chain) in various tissues, leading to organ dysfunction<ref>McKenna RW, et al., (2017). Plasma cell neoplasms: Monoclonal immunoglobulin deposition diseases, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p254-256.</ref> | ||
| − | *Underlying disorders are [[Plasma Cell Neoplasms|plasma cell neoplasms]] or rarely lymphoplasmacytic neoplasm | + | *Underlying disorders are [[HAEM4:Plasma Cell Neoplasms|plasma cell neoplasms]] or rarely lymphoplasmacytic neoplasm |
*Many patients at diagnosis have not developed overt myeloma or lymphoma | *Many patients at diagnosis have not developed overt myeloma or lymphoma | ||
*Even with low clonal neoplastic burden, systemic Ig deposition often results in aggressive disease progression and organ failure if untreated | *Even with low clonal neoplastic burden, systemic Ig deposition often results in aggressive disease progression and organ failure if untreated | ||
*While secreted monoclonal Ig products are soluble in most patients, some are amyloidogenic, and (more rarely) some are prone to form non-amyloid deposits | *While secreted monoclonal Ig products are soluble in most patients, some are amyloidogenic, and (more rarely) some are prone to form non-amyloid deposits | ||
| − | *There are two major types of monoclonal Ig deposition diseases: [[ | + | *There are two major types of monoclonal Ig deposition diseases: [[HAEM5:Immunoglobulin-related (AL) amyloidosis|primary amyloidosis]], or Ig light chain (AL) amyloidosis; and [[HAEM5:Monoclonal immunoglobulin deposition disease|light chain and heavy chain disposition diseases]] |
*Ig Heavy chain (AH) amyloidosis<ref>{{Cite journal|last=Eulitz|first=M.|last2=Weiss|first2=D. T.|last3=Solomon|first3=A.|date=1990-09|title=Immunoglobulin heavy-chain-associated amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/2118650|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=87|issue=17|pages=6542–6546|doi=10.1073/pnas.87.17.6542|issn=0027-8424|pmc=PMC54572|pmid=2118650}}</ref><ref>{{Cite journal|last=Solomon|first=A.|last2=Weiss|first2=D. T.|last3=Murphy|first3=C.|date=1994-02|title=Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/8141123|journal=American Journal of Hematology|volume=45|issue=2|pages=171–176|doi=10.1002/ajh.2830450214|issn=0361-8609|pmid=8141123}}</ref><ref>{{Cite journal|last=Miyazaki|first=Daigo|last2=Yazaki|first2=Masahide|last3=Gono|first3=Takahisa|last4=Kametani|first4=Fuyuki|last5=Tsuchiya|first5=Ayako|last6=Matsuda|first6=Masayuki|last7=Takenaka|first7=Yoshiaki|last8=Hosh|first8=Yoshinobu|last9=Ikeda|first9=Shu-ichi|date=2008-06|title=AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report|url=https://pubmed.ncbi.nlm.nih.gov/18484339|journal=Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis|volume=15|issue=2|pages=125–128|doi=10.1080/13506120802006229|issn=1744-2818|pmid=18484339}}</ref> and heavy-and-light-chain (AH/AL) amyloidosis are two rare forms of monoclonal Ig-related amyloidosis<ref>{{Cite journal|last=Nasr|first=Samih H.|last2=Said|first2=Samar M.|last3=Valeri|first3=Anthony M.|last4=Sethi|first4=Sanjeev|last5=Fidler|first5=Mary E.|last6=Cornell|first6=Lynn D.|last7=Gertz|first7=Morie A.|last8=Dispenzieri|first8=Angela|last9=Buadi|first9=Francis K.|date=2013-03|title=The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/23302715|journal=Kidney International|volume=83|issue=3|pages=463–470|doi=10.1038/ki.2012.414|issn=1523-1755|pmid=23302715}}</ref><ref>{{Cite journal|last=Chaulagain|first=Chakra P.|last2=Herlitz|first2=Leal C.|last3=Fu|first3=Julie|last4=Bilani|first4=Nadeem|last5=Lucitt|first5=Camerun|last6=Comenzo|first6=Raymond L.|date=2020-11|title=How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/32703752|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=20|issue=11|pages=e826–e831|doi=10.1016/j.clml.2020.06.017|issn=2152-2669|pmid=32703752}}</ref> | *Ig Heavy chain (AH) amyloidosis<ref>{{Cite journal|last=Eulitz|first=M.|last2=Weiss|first2=D. T.|last3=Solomon|first3=A.|date=1990-09|title=Immunoglobulin heavy-chain-associated amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/2118650|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=87|issue=17|pages=6542–6546|doi=10.1073/pnas.87.17.6542|issn=0027-8424|pmc=PMC54572|pmid=2118650}}</ref><ref>{{Cite journal|last=Solomon|first=A.|last2=Weiss|first2=D. T.|last3=Murphy|first3=C.|date=1994-02|title=Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/8141123|journal=American Journal of Hematology|volume=45|issue=2|pages=171–176|doi=10.1002/ajh.2830450214|issn=0361-8609|pmid=8141123}}</ref><ref>{{Cite journal|last=Miyazaki|first=Daigo|last2=Yazaki|first2=Masahide|last3=Gono|first3=Takahisa|last4=Kametani|first4=Fuyuki|last5=Tsuchiya|first5=Ayako|last6=Matsuda|first6=Masayuki|last7=Takenaka|first7=Yoshiaki|last8=Hosh|first8=Yoshinobu|last9=Ikeda|first9=Shu-ichi|date=2008-06|title=AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report|url=https://pubmed.ncbi.nlm.nih.gov/18484339|journal=Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis|volume=15|issue=2|pages=125–128|doi=10.1080/13506120802006229|issn=1744-2818|pmid=18484339}}</ref> and heavy-and-light-chain (AH/AL) amyloidosis are two rare forms of monoclonal Ig-related amyloidosis<ref>{{Cite journal|last=Nasr|first=Samih H.|last2=Said|first2=Samar M.|last3=Valeri|first3=Anthony M.|last4=Sethi|first4=Sanjeev|last5=Fidler|first5=Mary E.|last6=Cornell|first6=Lynn D.|last7=Gertz|first7=Morie A.|last8=Dispenzieri|first8=Angela|last9=Buadi|first9=Francis K.|date=2013-03|title=The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/23302715|journal=Kidney International|volume=83|issue=3|pages=463–470|doi=10.1038/ki.2012.414|issn=1523-1755|pmid=23302715}}</ref><ref>{{Cite journal|last=Chaulagain|first=Chakra P.|last2=Herlitz|first2=Leal C.|last3=Fu|first3=Julie|last4=Bilani|first4=Nadeem|last5=Lucitt|first5=Camerun|last6=Comenzo|first6=Raymond L.|date=2020-11|title=How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/32703752|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=20|issue=11|pages=e826–e831|doi=10.1016/j.clml.2020.06.017|issn=2152-2669|pmid=32703752}}</ref> | ||
==WHO Classification Pages (Includes Links to Content)== | ==WHO Classification Pages (Includes Links to Content)== | ||
| − | *[[ | + | *[[HAEM5:Immunoglobulin-related (AL) amyloidosis]] |
| − | *[[ | + | *[[HAEM5:Monoclonal immunoglobulin deposition disease]] |
==Other Related Pages (Includes Links to Content)== | ==Other Related Pages (Includes Links to Content)== | ||
| − | *[[Plasma Cell Neoplasms]] | + | *[[HAEM4:Plasma Cell Neoplasms]] |
| − | *[[Lymphoplasmacytic | + | *[[HAEM5:Lymphoplasmacytic lymphoma]] |
==Additional Information== | ==Additional Information== | ||
Latest revision as of 16:34, 4 December 2023
Primary Author(s)*
Chen Yang, MD, PhD
Graphical Data Links
None
General Disease Overview / Description of Cancer Category
- The major classification group of Monoclonal Immunoglobulin Deposition Diseases, as described in the revised 4th edition of the WHO, includes the categories: HAEM5:Immunoglobulin-related (AL) amyloidosis and HAEM5:Monoclonal immunoglobulin deposition disease
- The monoclonal immunoglobulin (Ig) deposition diseases are closely related disorders characterized by deposition of aberrant Ig (mostly light chain and rarely heavy chain) in various tissues, leading to organ dysfunction[1]
- Underlying disorders are plasma cell neoplasms or rarely lymphoplasmacytic neoplasm
- Many patients at diagnosis have not developed overt myeloma or lymphoma
- Even with low clonal neoplastic burden, systemic Ig deposition often results in aggressive disease progression and organ failure if untreated
- While secreted monoclonal Ig products are soluble in most patients, some are amyloidogenic, and (more rarely) some are prone to form non-amyloid deposits
- There are two major types of monoclonal Ig deposition diseases: primary amyloidosis, or Ig light chain (AL) amyloidosis; and light chain and heavy chain disposition diseases
- Ig Heavy chain (AH) amyloidosis[2][3][4] and heavy-and-light-chain (AH/AL) amyloidosis are two rare forms of monoclonal Ig-related amyloidosis[5][6]
WHO Classification Pages (Includes Links to Content)
Other Related Pages (Includes Links to Content)
Additional Information
None
References
- ↑ McKenna RW, et al., (2017). Plasma cell neoplasms: Monoclonal immunoglobulin deposition diseases, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p254-256.
- ↑ Eulitz, M.; et al. (1990-09). "Immunoglobulin heavy-chain-associated amyloidosis". Proceedings of the National Academy of Sciences of the United States of America. 87 (17): 6542–6546. doi:10.1073/pnas.87.17.6542. ISSN 0027-8424. PMC 54572. PMID 2118650. Check date values in:
|date=(help)CS1 maint: PMC format (link) - ↑ Solomon, A.; et al. (1994-02). "Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)". American Journal of Hematology. 45 (2): 171–176. doi:10.1002/ajh.2830450214. ISSN 0361-8609. PMID 8141123. Check date values in:
|date=(help) - ↑ Miyazaki, Daigo; et al. (2008-06). "AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report". Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis. 15 (2): 125–128. doi:10.1080/13506120802006229. ISSN 1744-2818. PMID 18484339. Check date values in:
|date=(help) - ↑ Nasr, Samih H.; et al. (2013-03). "The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis". Kidney International. 83 (3): 463–470. doi:10.1038/ki.2012.414. ISSN 1523-1755. PMID 23302715. Check date values in:
|date=(help) - ↑ Chaulagain, Chakra P.; et al. (2020-11). "How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)". Clinical Lymphoma, Myeloma & Leukemia. 20 (11): e826–e831. doi:10.1016/j.clml.2020.06.017. ISSN 2152-2669. PMID 32703752 Check
|pmid=value (help). Check date values in:|date=(help)
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
*The hierarchical tumour classification structure displayed on this page is reproduced from the WHO Classification of Tumours with permission from the copyright holder, ©International Agency for Research on Cancer.